Viatris Inc. VTRS
Viatris Inc. (Nasdaq: VTRS) is a specialty pharmaceutical company. Its next catalyst on record is Pacira acquisition: Transaction close (November 2026).
Upcoming catalysts
- November 2026Pacira acquisition — Transaction close
The transaction is expected to close by the end of November 2026.
- November 2026Biosimilars non-compete restrictions — Expiration of non-compete for U.S. market
These restrictions expired immediately at the time of close for all ex-U.S. markets and will expire in November 2026 for the U.S. market.
Next further out: Nashik manufacturing facility — Resume production (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Recent results and decisions
- Nov 5, 2026approval Viatris receives regulatory approval for RYZUMVI for presbyopia in the U.S.
Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan
Filing - Nov 5, 2026approval Viatris receives regulatory approval for WAKIX in Japan.
Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.